Twist Bioscience
TWST
246 hedge funds and large institutions have $3.08B invested in Twist Bioscience in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 89 increasing their positions, 84 reducing their positions, and 28 closing their positions.
196% more call options, than puts
Call options by funds: $5.99M | Put options by funds: $2.02M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
14% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 28
6% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 84
3% more capital invested
Capital invested by funds: $2.99B → $3.08B (+$96.5M)
0% more funds holding
Funds holding: 245 → 246 (+1)
1.29% less ownership
Funds ownership: 112.78% → 111.49% (-1.3%)
Top Buyers
Top Sellers
TWST Hedge Fund Activity: Q4 2024 in Review
246 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q4 2024, worth a combined $3.08B — up 3.2% from $2.99B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new TWST positions and 28 closed out — a net gain of 4 holders — while 89 added to existing stakes and 84 trimmed.
The largest buyer was First Light Asset Management, opening a new position worth an estimated $55.4M. The largest seller was JP Morgan Chase, cutting an estimated $30.6M.
- 246 institutional investors held Twist Bioscience (TWST) as of Q4 2024, up from 245 in Q3 2024.
- Funds reported $3.08B of Twist Bioscience stock for Q4 2024, up 3.2% quarter-over-quarter.
- 32 funds opened new Twist Bioscience positions in Q4 2024 and 28 closed out, a net change of +4 holders.
- The largest Twist Bioscience buyer in Q4 2024 was First Light Asset Management, an estimated $55.4M added.
- The largest Twist Bioscience seller in Q4 2024 was JP Morgan Chase, an estimated $30.6M sold.
Based on aggregated 13F filings for Q4 2024.